688131.SH
皓元医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 91.66
−5.88%Year over year
Reported trailing growth
- Revenue
- +26.5%
- EBITDA
- —
- EBIT
- +0.3%
- EPS
- -1.2%
- Free cash flow
- +343.6%
- Operating cash flow
- +20.5%
Forward estimates
Based on analyst estimates
- Revenue
- -38.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +28.4%
- EBITDA
- +21.0%
- EBIT
- +14.7%
- Net income
- +7.4%
- EPS
- -5.3%
- Free cash flow
- +23.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026